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Abstract
In the Iberian Peninsula, which includes mainly Spain and Portugal, large genomic rearrangements (LGRs) of BRCA1 and
BRCA2 have respectively been found in up to 2.33% and 8.4% of families with hereditary breast and/or ovarian cancer
(HBOC) that lack point mutations and small indels. In Galicia (Northwest Spain), the spectrum and frequency of BRCA1/
BRCA2 point mutations differs from the rest of the Iberian populations. However, to date there are no Galician frequency
reports of BRCA1/BRCA2 LGRs. Here we used multiplex ligation-dependent probe amplification (MLPA) to screen 651
Galician index cases (out of the 830 individuals referred for genetic analysis) without point mutations or small indels. We
identified three different BRCA1 LGRs in four families. Two of them have been previously classified as pathogenic LGRs: the
complete deletion of BRCA1 (identified in two unrelated families) and the deletion of exons 1 to 13. We also identified the
duplication of exons 1 and 2 that is a LGR with unknown pathogenicity. Determination of the breakpoints of the BRCA1
LGRs using CNV/SNP arrays and sequencing identif ied them as NG_005905.2:g.70536_180359del,
NG_005905.2:g.90012_97270dup, and NC_000017.10:g.41230935_41399840delinsAluSx1, respectively; previous observa-
tions of BRCA1 exon1-24del, exon1-2dup, and exon1-13del LGRs have not characterized them in such detail. All the BRCA1
LGRs arose from unequal homologous recombination events involving Alu elements. We also detected, by sequencing, one
BRCA2 LGR, the Portuguese founder mutation c.156_157insAluYa5. The low frequency of BRCA1 LGRs within BRCA1
mutation carriers in Galicia (2.34%, 95% CI: 0.61–7.22) seems to differ from the Spanish population (9.93%, 95% CI: 6.76–
14.27, P-value = 0.013) and from the rest of the Iberian population (9.76%, 95% CI: 6.69–13.94, P-value = 0.014).
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Introduction
The two major high-penetrance breast cancer susceptibility
genes, BRCA1 [1] and BRCA2 [2], account for approximately 26%
of all cases of hereditary breast and/or ovarian cancer (HBOC)
[3]. To date, some 1,700 BRCA1 variants and 1,900 BRCA2
variants have been reported (Breast Cancer Information Core
database, http://research.nhgri.nih.gov/bic/). However, only 81
BRCA1 variants and 17 BRCA2 variants are large genomic
rearrangements (LGRs) [4], and the prevalence of BRCA1/2
LGRs varies widely among different populations, mainly due to
the existence of founder rearrangements. For example, in the
Netherlands, BRCA1 LGRs constitute up to 27% of all BRCA1
mutations (see Sluiter et al. [4] and references therein), whereas to
date, only one BRCA2 LGR has been reported in a proband of
Dutch and German ancestry [5]. On the contrary, in Portugal
BRCA1 LGRs represents the ,6% of BRCA1 mutations while, due
to the Portuguese BRCA2 founder mutation c.156_157insAluYa5,
the frequency of BRCA2 LGRs is the highest reported to date
(57.89% of BRCA2 mutations) [6–8].
Of the published studies of the frequency of BRCA1/2 LGRs in
the Iberian Peninsula or regions thereof [6–17], none has
specifically examined the population of Galicia (NW Spain), a
region with a distinct genetic identity attributable to its historical
relative isolation, its cultural identity, and the occurrence of a
marked population bottleneck around 1000 years ago [18]. This
population features a number of founder mutations [18–20],
including a BRCA1 mutation, c.211A.G (referred to
NM_007294.3; BIC 330A.G), which is present in more than
50% of Galician HBOC families with BRCA1/2 mutations [21].
In view of to date there are no Galician frequency reports of
BRCA1/BRCA2 LGRs and the observed differences between
Galicia and the rest of Spain in regard to the spectrum and
prevalence of point mutations of BRCA1 and BRCA2, we decided
to investigate whether a similar situation holds for BRCA1/2
LGRs. We accordingly screened for BRCA1/2 LGRs among
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Galician families referred for genetic examination of BRCA1/2.
Here we describe three novel BRCA1 LGRs, propose likely
originating mechanisms, and compare the frequency of LGRs in




Our reference laboratory handles essentially all Galician
patients referred for evaluation of the possibility of HBOC by
means of DNA analysis. Between 1997 and 2012 we examined
BRCA1/2 in 830 patients referred to us in accordance with the
criteria established in Galician oncological guidelines [22], which
currently recommend referral if patients have (i) three or more first
degree relatives who have suffered breast or ovarian cancer, (ii)
two affected first degree relatives if one was aged ,40 years at
diagnosis, (iii) two affected first or second degree relatives if both
suffered breast cancer at age ,50 years, or if one suffered bilateral
breast cancer and one was aged ,50 years at diagnosis, or if at
least one of these cancers was ovarian or a male breast cancer, (iv)
age ,30 years at diagnosis of a breast cancer, (v) both breast and
ovarian cancer, (vi) bilateral breast cancer diagnosed before the
age of 40 years, or (vii) a family history of deleterious mutation of a
breast cancer susceptibility gene. These patients were first screened
for the founder mutations BRCA2 c.156_157insAluYa5 and
BRCA1 c.211A.G (BIC 330A.G) using protocols respectively
described by Peixoto et al. [7] and Vega et al. [21], after which
other BRCA1/2 mutations were sought by bi-directional sequenc-
ing of exons and flanking intronic splice sites. Of the 830 referred
patients, 125 were found to have point mutations or small indels in
BRCA1, and 54 point mutations or small indels in BRCA2. The 651
with no point mutations or small indels were included in the
present study, as were members of their families when this was
appropriate and possible.
Relationships between index cases were investigated through
the genealogical tree, which include at least three generations, and
the family name that in Spain included the surname from the
father and also from the mother.
Ethics Statement
The study conformed to Spanish biomedical research legislation
(Ley 14/2007) and was approved by the Galician Ethical
Committee for Clinical Research. All participants gave written
informed consent.
LGR screening
Screening for LGRs in BRCA1 and BRCA2 was performed by
multiplex ligation-dependent probe amplification (MLPA). The
commercial BRCA1 kits P002 (primary screening) and P087
(confirmatory) and the BRCA2 kit P045 were used in accordance
with the manufacturer’s instructions [23]. Fragment electropho-
resis was performed on an Applied Biosystems 3730 xl DNA
analyzer using GeneScan 500 LIZ size standards (Applied
Biosystems, USA) and at least 24 samples in each run, and the
resulting data were analyzed using GeneMapper software (Applied
Biosystems, USA). Visual peak pattern evaluation was carried out
following the manufacturer’s recommendations. After exclusion of
samples failing the first quality control, the remaining samples
were analyzed using Coffalyser v8 software in ‘‘direct analysis’’
normalization mode using concurrently run samples as the
reference set and taking the medians of the corresponding
normalized probe signal ratios. When all sample signals had been
normalized in this way, any samples with aberrant probe signals
(.0.15 standard deviations from the mean) were removed, the
whole normalization process was repeated, and so on until the
standard deviations of all probe signals were ,0.15.
SNP arrays and analysis of breakpoint regions
LGRs were characterized using the Cytogenetics Whole-
Genome 2.7 M Array in combination with the Genome-Wide
Human SNP Array 6.0, or alternatively the CytoScan HD Array
(all from Affymetrix). The results were analyzed with the
Chromosome Analysis Suite (Affymetrix), the breakpoint regions
delimited by the array markers were examined in the UCSC
Genome Browser (http://genome.ucsc.edu/; assembly NCBI37/
hg19), and repetitive sequences in these regions were identified
using RepeatMasker [24] within the Genome Browser. Breaks
were pinpointed by sequencing as next described.
Sequencing
PCR primers were designed using Primer3 software (http://
frodo.wi.mit.edu/primer3/); primer sequences and PCR condi-
tions are described in the Table S1. Sequencing was performed
using BigDye Terminator v3.1 sequencing kits (Applied Biosys-
tems, USA). Electrophoresis was carried out on an ABI 3730 xl
DNA analyzer (Applied Biosystems, USA).
Statistical analyses
Association tests were performed using two-degrees of freedom
Pearson’s chi-square test with Yates correction. Statistical analyses
were performed using the statistical package stats with the software
R v3.0.2. A nominal P-value of 0.05 was considered significant.
Results
Among the 651 apparently unrelated index cases studied we
found four different LGRs, three in BRCA1 by MLPA and one in
BRCA2 by sequencing (Table 1).
Exon1-2dup
A duplication of BRCA1 exons 1-2 was identified in a 66-year-
old woman in whom breast cancer was diagnosed at age 64 years.
Previously, her three sisters had developed breast cancer (at ages
35, 49 and 59 years), as had her two maternal aunts (according to
the family, though this was not confirmed) (Family I, Fig. 1). The
SNP array bracketed the downstream breakpoint but not the
upstream one (Fig. 1c; throughout this paper, ‘‘upstream’’ and
‘‘downstream’’ respectively refer to the directions of decreasing
and increasing genomic coordinates). However, sequencing
identified a hybrid Alu element in which AluYk4 and AluY, two
of the ten Alu elements identified by RepeatMasker in the
bracketed region and its upstream vicinity (Fig. 1d), overlapped by
48 nt (Fig. 1e), indicating the tandem repetition of BRCA1 exons
1A, 1B and 2 through duplication of the 7,259-nt sequence
NG_005905.2:g.90012_97270. The origin of the duplication was
thus an unequal homogolous recombination event that created the
hybrid Alu element at the point of recombination. Note that since
non-coding BRCA1 exon 1A shares part of its sequence with non-
coding NBR2 exon 1 (the two exons together forming a
bidirectional promoter regulated by different transcriptional
repressor factors), the duplication of BRCA1 exons 1 and 2 also
means the duplication of part of the neighboring gene (NBR2 exon
1). Unfortunately, a co-segregation study could not be performed
since the affected family members were deceased.
Exon1-24del
The complete deletion of BRCA1 was identified in two
presumably unrelated Galician families. In Family II the index
Large Genomic Rearrangements of BRCA1 and BRCA2


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Large Genomic Rearrangements of BRCA1 and BRCA2
PLOS ONE | www.plosone.org 3 March 2014 | Volume 9 | Issue 3 | e93306
patient was a 49-year-old woman in whom breast cancer was
diagnosed at age 45 years (Fig. 2a). Breast cancer had also been
diagnosed in her paternal grandmother (at age 60 years), in a half-
cousin on her father’s side (at age 30 years), and in her great-
grandmother, although this last case was not confirmed. In Family
III the deletion of exons 1-24 was detected in a 50-year-old woman
who had sought genetic evaluation following identification of this
deletion in her sister, in whom breast cancer had been diagnosed
at age 46 years (the sister had been evaluated in another laboratory
and pedigree data were not made available to us). In the present
study, SNP array analysis showed that in both the affected families
the deletion includes NBR2 and BRCA1 (Fig. 2c), and in both cases
amplification and sequencing of the junction region identified a
segment in which AluSq2 and AluY, two of the five Alu elements
located by RepeatMasker in the breakpoint regions (Fig. 2d),
shared a sequence of 20 nucleotides (Fig. 2e). We accordingly
identify this LGR as the 109,824 bp deletion
NG_005905.2:g.70536_180359del, and as attributable to unequal
homologous recombination.
Exon1-13del
Deletion of BRCA1 exons 1-13 was detected in a 49-year-old
woman in whom bilateral breast cancer was diagnosed at 35 and
40 years of age. One of her paternal cousins and a maternal aunt
had also developed breast cancer (at ages 35 and 40 years,
respectively), and another paternal cousin developed ovarian
cancer at age 40 years (Fig. 3a). In the downstream breakpoint
region delimited by the SNP array (Fig. 3c) RepeatMasker showed
two Alu elements (Fig. 3d). In the putative upstream breakpoint
region it found no repetitive elements, but did find several further
upstream. Using a forward primer hybridizing on a non-repetitive
sequence (Table S1), we were able to identify a segment in which
one of the downstream Alu elements, AluSc8, shares 41
nucleotides with an AluSx1 (Fig. 3e), the initial 173-nt segment
Figure 1. BRCA1 exon1-2dup. a) Pedigree of Family I. +: mutation carrier; -: mutation non-carrier. b) MLPA normalized ratio results. Dark blue:
reference signal for each probe created as described under Material and Methods. Light blue: sample probes with ratios $0.7 and #1.3. Red: sample
probes with ratios .1.3 or ,0.7. c) Location of the downstream breakpoint region on the forward strand, as delimited (arrows) by SNP array results.
Genes on the forward strand are shown in blue and genes on the reverse strand in green. d) Repetitive elements identified by RepeatMasker in the
breakpoint region. e) Overlapping AluY and AluYk4 sequences at the junction between the repeated sequences containing exons 1 and 2.
doi:10.1371/journal.pone.0093306.g001
Large Genomic Rearrangements of BRCA1 and BRCA2
PLOS ONE | www.plosone.org 4 March 2014 | Volume 9 | Issue 3 | e93306
of which is homologous with the initial segment of AluSq2, the first
upstream Alu element (see Figure S1). This LGR therefore seems
to have arisen through an unequal homologous recombination
event involving the deletion of the 168,905-bp sequence
NC_000017.10:41230935_41399840 and its replacement with
AluSx1 (doubtless favored by the homology with AluSq2).
384insAlu
Routine screening detected the Portuguese founder mutation
BRCA2 c.156_157insAluYa5 in a Galician woman in whom breast
cancer was diagnosed at 41 years of age. Her niece, her deceased
sister, her father and two aunts (one on each side) had also
developed breast cancer (Fig. 4).
In the various studies describing BRCA1 and/or BRCA2 LGRs
in diverse regions of the Iberian Peninsula (Table 2), the reported
frequency of BRCA1 LGRs among HBOC families without point
mutations or small indels ranges from 0.48% to 2.33%, and that of
BRCA2 LGRs from 0% to 8.4%. The difference between the
deleterious LGRs frequency in Galicia and in Spanish population
or in the rest Iberian populations is statistically significant (Table 3.
Chi-square test with Yates correction P-value = 0.013 or 0.014,
respectively).
Discussion
In the present study we have identified three LRGs in BRCA1
and one in BRCA2. The duplication of exons 1 and 2, that is a
variant of unknown significance, has been reported previously in a
Spanish HBOC family, but was not characterized in detail [12].
Therefore, although it is plausible that both rearrangements share
the same breakpoint, it cannot be assessed. The complete deletion
of BRCA1 has in the past been reported five times, three cases
concerning Spaniards [9,16,25], one a Central European patient
[26] and the fifth a German [27], but only in one of these cases,
Figure 2. BRCA1 exon1-24del. a) Pedigree of Family II. +: mutation carrier; -: mutation non-carrier. b) MLPA normalized ratio results (color key as for
Fig. 1). c) Location of breakpoint regions on the forward strand, as delimited (arrows) by SNP array results (gene color key as for Fig. 1). d) Repetitive
elements identified by RepeatMasker in the breakpoint regions. e) Overlapping AluY and AluSq2 sequences at the junction (red letters indicate
deleted segments).
doi:10.1371/journal.pone.0093306.g002
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Figure 3. BRCA1 exon1-13del. a) Pedigree of Family IV. +: mutation carrier; -: mutation non-carrier. b) MLPA normalized ratio results (color key as
for Fig. 1). c) Location of breakpoint regions on the forward strand, as delimited (arrows) by SNP array results (gene color key as for Fig. 1). d)
Repetitive elements identified by RepeatMasker in the breakpoint regions, with a red frame highlighting the AluSq2 element replaced by AluSx1 in
the patient. e) Overlapping AluSx1 and AluSc8 sequences at the junction (red letters indicate deleted segments, and forward and reverse sequences
are shown because of the poly-A tail of AluSc8).
doi:10.1371/journal.pone.0093306.g003
Figure 4. BRCA2 c.156_157insAluYa5. Pedigree of Family V. +: mutation carrier; -: mutation non-carrier.
doi:10.1371/journal.pone.0093306.g004
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that identified a de novo BRCA1 deletion, were the breakpoints
characterized [25]. It is interesting that none of the three complete
BRCA1 deletions with published length estimates can share both
breakpoints, their lengths being ,110 kb (this work), 259–345 kb
[27], and ,150 kb [25] (this last deletion extending from the
beginning of NBR1 to VAT1 and including the whole of RND2,
yBRCA1, BRCA1 and NBR2). The deletion of BRCA1 exons 1-13
has previously been reported in three families, two Spanish [12,16]
and one Finnish [28]. It is unclear whether either of the
breakpoints of this deletion
(NC_000017.10:41230935_41399840) coincides with or lies close
to the corresponding breakpoint of the approximately 250 kb
exon1-13del LGR reported by del Valle et al. [12]: both these
deletions eradicate NBR2, NBR1 and TMEM106A as well as
BRCA1 exons 1-13. However, the present LGR does not affect
ARL4D, whereas Del Valle et al. [12] only identified their
downstream breakpoint as lying somewhere between exon 6 of
TMEM106A and exon 2 of ARL4D. Concerning the BRCA2
c.156_157insAluYa5 mutation, Peixoto et al. [8] recently reported
finding this mutation in only three out of 5,294 families living
outside Portugal all three of which had emigrated relatively
recently from Portugal. This is therefore, as far as we know, the
first report of c.156_157insAluYa5 in a family not known to be of
Portuguese origin. However, recent generations of our patient’s
family have resided near the frontier between Spain and northern
Portugal, where a high frequency of this founder mutation has
been reported [7]. Although the absence of Portuguese ancestors
in the past four generations has been reported by the family, the
estimated age of the mutation, 5616215 years (estimated by the
study of 19 SNPs and nine microsatellite markers spanning
,2 Mb within and around BRCA2 [8]) makes plausible a
Portuguese origin for the mutation in our family.
Clinical classification of the identified LGRs
BRCA1 deletions of exons 1-13 and 1-24 are considered
pathological LGR [12]. In both cases the transcription start sites
are removed, likely resulting in the lack of the transcript.
Accordingly to Peixoto et al. [7], BRCA2 c.156_157insAluYa5 is
classified as deleterious since it results in exon 3 skipping and co-
segregates with the disease. However, the pathogenicity of the
duplication of BRCA1 exons 1-2 cannot be assessed. Despite the
efforts carried out by del Valle et al. [12] and by us to study the
effect at the RNA level we were unable to amplify the aberrant
allele. Moreover, a co-segregation study could not be performed in
none of the families identified in each report. Therefore, this
variant must remain as of uncertain significance.
Homologous vs. non-homologous recombination as the
origin of BRCA1/2 LGRs
Having identified non-homologous recombination events as the
sources of three of the four BRCA2 LGRs they analyzed, Ruiz de
Garibay et al. suggested that the proportion of BRCA2 LGRs
originated by homologous recombination had been overestimated
[14]. For BRCA1 LGRs, the present results are in keeping with
statistics showing the predominant mechanism to be Alu-mediated
homologous recombination [4]. Furthermore, all the Alu elements
apparently involved in producing the BRCA1 LGRs observed in
the present study are members of the evolutionarily youngest
subfamilies, AluS and AluY, which have a high degree of mutual
homology [29].
BRCA1/2 LGRs in the Iberian Peninsula
Founder mutations are responsible for the high rates of LGRs in
the Valencian Community (Eastern Spain), where
NG_005905:g.97346_111983del has deleted BRCA1 exons 3-5
in 10.97% of all families with mutations in the BRCA1 gene [30],
and in Portugal, where BRCA2 c.156_157insAluYa5
(NG_012772:g.8686_8687ins AluYa5) accounts for 57.89% of all
mutant BRCA2 families [8]. By contrast, in our population
deleterious LGRs constitute only 2.34% (95% CI: 0.61–7.22) of
all families with definitely pathogenic BRCA1 variants, given the
small duplication exon1-2dup cannot be classified as a deleterious
mutation. The observed frequency it is the lowest rate reported to
date for BRCA1 LGRs in an Iberian population. We should
however note that given that most of the studies performed to date
in Iberian populations are characterized by their limited sample
size, the accuracy of the estimates is limited, as it is demonstrated
by the wide interval of the frequency at 95% confidence level.
Nonetheless, the frequency of BRCA1 LGRs within BRCA1
mutation carriers in Galician population seems to differ from
Spanish (P-value = 0.013) and Iberian populations (P-val-
ue = 0.014).
Role of MLPA in testing for BRCA1/2 LGRs
MLPA is a fast, sensitive means of detecting LGRs, and cannot
at present be replaced by massively parallel sequencing methods:
recent studies suggest that these latter are adequate for detection of
point mutations of BRCA1 and BRCA2, but are insufficiently
specific for LGRs [31]. However, the optimization of next
generation sequencing standard protocols for detection of Alu
element rearrangements have resulted in false positive reads [32].
The shortcoming of MLPA is that it does not identify LGR
breakpoints, as is necessary for recognition of recurrent rear-
rangements, for inference of the molecular mechanisms of
rearrangement, and for rapid analysis of a proband’s relatives.
Breakpoint identification still requires other strategies, such as
Table 3. Frequency of BRCA1 and BRCA2 deleterious LGRs.
Galicia Spaina Iberian populationb Galicia vs Spain Galicia vs Iberian populations
N % (95% CI) N % (95% CI) N % (95% CI) P-valuec P-valuec
NLGR 3 2.34 (0.61–7.22) 27 9.93 (6.76–14.27) 28 9.76 (6.69–13.94) 0.013 0.014
NBRCA1+ 128 272 287
NLGR: number of families with LGRs; NF_BRCA1+: number of families with BRCA1 mutations.
aEstimated from the reports performed in Spanish populations with available data [9,11,15,16].
bEstimated from the reports performed in Iberian populations with available data [6,7,9,11,15,16].
cChi-square test with Yates correction P-value.
doi:10.1371/journal.pone.0093306.t003
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methods based on Sanger sequencing. Another question is
whether MLPA should be performed before or after screening
for point mutations and small indels. Given the relatively high
frequency of LGRs they found among BRCA1 mutations in Spain,
8.2%, de la Hoya et al. [9] suggested that screening for LGRs by
MLPA should be the first test performed in the evaluation of
BRCA1 in Spanish subjects, since this would speed results for a
considerable number of families. Others have proposed the first-
line use of MLPA on the grounds of cost effectiveness [33,34].
However, the low frequency of LGRs found in the present study
among Galician families with BRCA1/2 mutations does not justify
this strategy in this region.
In conclusion, we have detected three BRCA1 large rearrange-
ments in four families and have determined their breakpoints.
Two of these three LGRs, which are classified as deleterious
mutations, account for 0.61% of referrals without point mutations
or small indels in BRCA1, and 2.34% of all families with BRCA1
mutations in Galicia, the lowest figure reported to date in the
Iberian population. All three involve Alu elements, which
corroborates the predominance of Alu-mediated mechanisms in
the production of BRCA1 LGRs. LGRs affecting the same exons
have been reported previously, but without breakpoint determi-
nation, and in some cases cannot have coincided with those
observed in this study. We also detected one BRCA2 LGR, the
Portuguese founder mutation c.156_157insAluYa5. To our
knowledge, this is the first time this mutation has been detected
in a family not known to be of Portuguese origin. However, a
distant Portuguese ancestry cannot be ruled out.
Supporting Information
Figure S1 AluSq2 replacement by AluSx1 in
NC_000017.10:g.41230935_41399840delinsAluSx1. a) Pa-
tient’s electropherogram. b) Reference sequence, patient sequence,
and AluSx1 sequence (Repbase Sequences). c) Blastn suite.
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30. Palanca S, de Juan I, Perez-Simó G, Barragán E, Chirivella I, et al. (2013) The
deletion of exons 3–5 of BRCA1 is the first founder rearrangement identified in
breast and/or ovarian cancer Spanish families. Fam Cancer 12: 119–123.
Large Genomic Rearrangements of BRCA1 and BRCA2
PLOS ONE | www.plosone.org 9 March 2014 | Volume 9 | Issue 3 | e93306
31. Feliubadalo L, Lopez-Doriga A, Castellsague E, del Valle J, Menendez M, et al.
(2012) Next-generation sequencing meets genetic diagnostics: development of a
comprehensive workflow for the analysis of BRCA1 and BRCA2 genes.
Eur J Hum Genet.
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